These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 23118110)

  • 1. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.
    Zannin ME; Birolo C; Gerloni VM; Miserocchi E; Pontikaki I; Paroli MP; Bracaglia C; Shardlow A; Parentin F; Cimaz R; Simonini G; Falcini F; Corona F; Viola S; De Marco R; Breda L; La Torre F; Vittadello F; Martini G; Zulian F
    J Rheumatol; 2013 Jan; 40(1):74-9. PubMed ID: 23118110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis.
    Cecchin V; Zannin ME; Ferrari D; Pontikaki I; Miserocchi E; Paroli MP; Bracaglia C; Marafon DP; Pastore S; Parentin F; Simonini G; De Libero C; Falcini F; Petaccia A; Filocamo G; De Marco R; La Torre F; Guerriero S; Martino S; Comacchio F; Muratore V; Martini G; Vittadello F; Zulian F
    J Rheumatol; 2018 Aug; 45(8):1167-1172. PubMed ID: 29657140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
    Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
    Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis.
    Zulian F; Balzarin M; Falcini F; Martini G; Alessio M; Cimaz R; Cimino L; Zannin ME
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):821-5. PubMed ID: 20191477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K; Orban I; Brodszky V; Bazso A; Balogh Z; Poor G; Kiss E
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
    Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
    Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis.
    Trachana M; Pratsidou-Gertsi P; Pardalos G; Kozeis N; Badouraki M; Kanakoudi-Tsakalidou F
    Scand J Rheumatol; 2011 Mar; 40(2):101-7. PubMed ID: 21108543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K; Garbutt J; Toib D; Mao J; King A; White A; French A
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High doses of infliximab in the management of juvenile idiopathic arthritis.
    Tambralli A; Beukelman T; Weiser P; Atkinson TP; Cron RQ; Stoll ML
    J Rheumatol; 2013 Oct; 40(10):1749-55. PubMed ID: 23950184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective case review of pediatric patients with uveitis treated with infliximab.
    Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
    Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.
    Simonini G; Taddio A; Cattalini M; Caputo R; De Libero C; Naviglio S; Bresci C; Lorusso M; Lepore L; Cimaz R
    Arthritis Care Res (Hoboken); 2011 Apr; 63(4):612-8. PubMed ID: 21452272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J; Otten MH; Gorter SL; Prince FH; van Rossum MA; van den Berg JM; van Pelt PA; Kamphuis S; Brinkman DM; Swen WA; Swart JF; Wulffraat NM; Dolman KM; Koopman-Keemink Y; Hoppenreijs EP; Armbrust W; ten Cate R; van Suijlekom-Smit LW
    Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.
    Tynjälä P; Kotaniemi K; Lindahl P; Latva K; Aalto K; Honkanen V; Lahdenne P
    Rheumatology (Oxford); 2008 Mar; 47(3):339-44. PubMed ID: 18238789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA; Thompson DJ; Whitcup SM; Suhler E; Clarke G; Smith S; Robinson M; Kim J; Barron KS
    Arthritis Rheum; 2005 Feb; 53(1):18-23. PubMed ID: 15696578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease.
    Sharma SM; Ramanan AV; Riley P; Dick AD
    Ann Rheum Dis; 2007 Jun; 66(6):840-1. PubMed ID: 17170050
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.